Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: Correlation of protein expression and GC/TOF-MS-based metabolomics

Oncology Reports

Volumn 25, Issue 4, 2011, Pages 1005-1012

  Buckendahl, Ann Christin ^a   Budczies, Jan ^a   Fiehn, Oliver ^b   Darb Esfahani, Silvia ^a   Kind, Tobias ^b   Noske, Aurelia ^c   Weichert, Wilko ^d   Sehouli, Jalid ^a   Braicu, Elena ^a   Dietel, Manfred ^a   Denkert, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

AMP activated protein kinase; Energy metabolism; Immunohistochemistry; Metabolomics; Ovarian carcinoma

Indexed keywords

FRUCTOSE; GLUCOSE; GLUCOSE 1 PHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; SORBITOL; SUCROSE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GRADING; CANCER STAGING; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; FEMALE; GAS CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METABOLOMICS; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TIME OF FLIGHT MASS SPECTROMETRY; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; METABOLOMICS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; PROGNOSIS; PROTEIN KINASES; SURVIVAL RATE;

EID: 79952215103     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1162     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer Statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HYS and Pecorelli S: Carcinoma of the ovary. Int J Gynaecol Obstet 83 (Suppl. 1): S135-S166, 2003.
3. Claudino WM, Quattrone A, Biganzoli L, Pestrin M, Bertini I and Di Leo A: Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol 25: 2840-2846, 2007. (Pubitemid 47123194)
4. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
5. Hardie DG: AMP-activated protein kinase: a key system mediating metabolic responses to exercise. Med Sci Sports Exerc 36: 28-34, 2004.
6. Hardie DG, Hawley SA and Scott JW: AMP-activated protein kinase - development of the energy sensor concept. J Physiol 574: 7-15, 2006. (Pubitemid 43905792)
7. Hardie DG: AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774-785, 2007.
8. Carling D: The AMP-activated protein kinase cascade - a unifying system for energy control. Trends Biochem Sci 29: 18-24, 2004.
9. Carling D: AMP-activated protein kinase: balancing the scales. Biochimie 87: 87-91, 2005.
10. Bolster DR, Crazier SJ, Kimball SR and Jefferson LS: AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 277: 23977-23980, 2002. (Pubitemid 34951907)
11. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C and Blenis J: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24: 200-216, 2004. (Pubitemid 38010048)
12. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR and Hardie DG: Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2: 28, 2003.
13. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M and Carling D: LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13: 2004-2008, 2003.
14. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA and Cantley LC: The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101: 3329-3335, 2004. (Pubitemid 38338195)
15. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Hoglund P, Jarvinen H, Kristo P, Pelin K, Ridanpaa M, Salovaara R, Tora T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, De la Chapelle A and Aaltonen LA: A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391: 184-187, 1998. (Pubitemid 28092478)
16. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Muller O, Back W and Zimmer M: Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18: 38-43, 1998. (Pubitemid 28027876)
17. Xiang X, Saha AK, Wen R, Ruderman NB and Luo Z: AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 321: 161-167, 2004. (Pubitemid 39055618)
18. Saitoh M, Nagai K, Nakagawa K, Yamamura T, Yamamoto S and Nishizaki T: Adenosine induces apoptosis in the human gastric cancer cells via an intrinsic pathway relevant to activation of AMP-activated protein kinase. Biochem Pharmacol 67: 2005-2011, 2004.
19. Campàs C, Lopez JM, Santidrián AF, Barragán M, Bellosillo B, Colomer D and Gil J: Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood 101: 3674-3680, 2003. (Pubitemid 36857958)
20. Meisse D, van de Casteele M, Beauloye C, Hainault I, Kefas BA, Rider MH, Foufelle F and Hue L: Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells. FEBS Lett 526: 38-42, 2002. (Pubitemid 35245688)
21. Misra P: AMP activated protein kinase: a next generation target for total metabolic control. Expert Opin Ther Targets 12: 91-100, 2008.
22. Silverberg SG: Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19: 7-15, 2000.
23. Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, Niesporek S, Könsgen D, Dietel M and Fiehn O: Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 66: 10795-10804, 2006. (Pubitemid 44876975)
24. Weckwerth W, Wenzel K and Fiehn O: Process for the integrated extraction, identification and quantification of metabolites, proteins and RNA to reveal their co-regulation in biochemical networks. Proteomics 4: 78-83, 2004. (Pubitemid 38140876)
25. Denkert C, Budczies J, Weichert W, Wohlgemuth G, Scholz M, Kind T, Niesporek S, Noske A, Buckendahl A, Dietel M and Fiehn O: Metabolite profiling of human colon carcinoma - deregulation of TCA cycle and amino acid turnover. Mol Cancer 18: 72, 2008.
26. Wishart DS, Knox C, Guo AC, et al: HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 37: D603-D610, 2009.
27. Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-10273, 2006. (Pubitemid 44799743)
28. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN and Gonzalez-Angulo AM: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27: 3297-3302, 2009.
29. Gambhir SS: Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 9: 683-693, 2002.
30. Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer 11: 891-899, 2004.
31. Issaq HJ, Nativ O, Waybright T, Luke B, Veenstra TD, Issaq EJ, Kravstov A and Mullerad M: Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J Urol 179: 2422-2426, 2008.
32. Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC and Nicholson JK: Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2: 2692-2703, 2007.
33. Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, Geisler JP, Miller G, Sellers T, Cliby W, Qian F, Keitz B, Intengan M, Lele S and Alderfer JL: Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer 113: 782-788, 2005. (Pubitemid 40101260)